Comparison of post-rmission stratgis in acut myloid lukmia: Autologous hmatopoitic stm cll transplantation vrsus consolidation chmothrapy
Hematology Reports, cilt.12, sa.3, ss.51-54, 2020 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 12 Sayı: 3
- Basım Tarihi: 2020
- Doi Numarası: 10.4081/hr.2020.8380
- Dergi Adı: Hematology Reports
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
- Sayfa Sayıları: ss.51-54
- Anahtar Kelimeler: Acute myeloid leukemia, Autolo-gous hematopoietic stem cell transplantation, Consolidation chemotherapy, Leukemia relapse, Prognosis
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Hayır
Özet
Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) has become a therapeutic option for first-line consolidation in Acute Myeloid Leukemia (AML) patients with favorable and intermediate risk features. A total of 101 AML patients in first complete remission, who were not eligible for allogeneic HSCT, were randomized to receive intensive cytarabine-based chemotherapy or to undergo auto-HSCT. The probability of LFS was significantly better in auto-HSCT recipients compared to chemotherapy arm (43% vs 4.8%, p=0.008). At the end of 915 (30-4470) days of follow-up, the probability of overall survival was better in auto-HSCT group compared to chemotherapy, without statistical significance (79.2% vs 38.8%, p=0.054). Multivariate analysis revealed a significant predictive impact of cytogenetic risk status on OS (p=0.002, HR: 2.824, 95% CI: 1.445-5.521). Auto-HSCT is considered as an effective consolidation approach in favorable and intermadiate risk AML patients.